Graham Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Graham Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,071	Closed	-$228K	–	1156
2025 Q4	$228K	Buy	+1,071	New	+$221K	0.01%	981
2024 Q4	–	Sell	-1,872	Closed	-$280K	–	1225
2024 Q3	$280K	Sell	1,872 -630	-25%	-$85.1K	﹤0.01%	804
2024 Q2	$341K	Buy	+2,502	New	+$340K	0.01%	688
2022 Q3	–	Sell	-9,466	Closed	-$879K	–	1058
2022 Q2	$879K	Buy	+9,466	New	+$892K	0.04%	481

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Graham Capital Management's ASND Position: Q1 2026 in Review

Graham Capital Management sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 1,071 shares — an estimated $228K sold.

Graham Capital Management first reported a position in ASND in Q2 2022 and held it in 4 quarters. The position peaked at $879K in Q2 2022. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Graham Capital Management reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 1,071 Ascendis Pharma A/S shares in Q1 2026, an estimated $228K.
Graham Capital Management first reported a position in Ascendis Pharma A/S in Q2 2022 and held it in 4 quarters.
Graham Capital Management's Ascendis Pharma A/S position peaked at $879K in Q2 2022.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.